CTKB Stock Analysis: Buy, Sell, or Hold?
CTKB - Cytek Biosciences, Inc. Common Stock
$4.28
-0.04 (-1.04%)
▼
5d:
-9.24%
30d:
-4.58%
90d:
-16.18%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When CTKB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CTKB is fairly valued with market pricing in 1.3% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: CTKB is fairly valued with market pricing in 1.3% annual growth. Fine to hold or accumulate slowly on dips.
In-depth Analysis How we analyze
Valuation Analysis: CTKB is currently trading at $4.28, which is considered slightly low relative to its 30-day fair value range of $4.20 to $4.53. The stock's valuation (Forward PE: 96.0) is in line with its historical norms (92.2). At these levels, the market is pricing in 1.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTKB is in a downtrend. Immediate support is located at $4.14, while resistance sits at $4.75.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+38.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CTKB is in a downtrend. Immediate support is located at $4.14, while resistance sits at $4.75.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.00 (+38.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$4.20 -
$4.53
Company Quality Score
46/100
(HOLD)
Options IV Signal
47th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
78.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 47th percentile)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.9% below Wall St target ($6.00)
- NEUTRAL: Market pricing in 1.3% annual earnings growth - fairly valued
- CAUTION: Recommendation downgraded due to -9.2% 5-day decline
Fair Price Analysis
30-Day Fair Range
$4.20 -
$4.53
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$0.54
(12.7%)
Support & Resistance Levels
Support Level
$4.14
Resistance Level
$4.75
Current Trend
Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
96.00
Wall Street Target
$6.00
(+38.9%)
Revenue Growth (YoY)
8.1%
Earnings Growth (YoY)
73.5%
Profit Margin
-33.0%
Valuation Premium vs History
+1.3% premium
PE vs Historical
96.0 vs 92.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.3%
(market-implied from PE analysis)
1-Year Target
$4.38
(+1%)
2-Year Target
$4.43
(+3%)
3-Year Target
$4.49
(+4%)
3-Yr Target (if PE normalizes)
(PE: 96→92)
PE COMPRESSION
$4.31
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: March 30, 2026 3:08 PM ET
Data refreshes hourly during market hours. Next update: 4:08 PM
Data refreshes hourly during market hours. Next update: 4:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTKB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 61 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$96 | 50 HOLD |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$93 | 59 HOLD |
